Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2026)

Neurocrine Biosciences' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Amortization of Deferred Charges fell 62.5% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.6 million (up 202.56% YoY) and the FY2023 annual result came in at $700000.0, down 41.67% from the prior year.
• Amortization of Deferred Charges was $2.7 million for Q1 2026 at Neurocrine Biosciences, down from $6.6 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $7.2 million in Q1 2025 and bottomed at $100000.0 in Q4 2023.
• A 5-year average of $2.0 million and a median of $300000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2025 — Amortization of Deferred Charges soared 2100.0% — and 2026, when it plunged 62.5%.
• Neurocrine Biosciences' Amortization of Deferred Charges stood at $200000.0 in 2022, then plunged by 50.0% to $100000.0 in 2023, then jumped by 200.0% to $300000.0 in 2024, then surged by 2100.0% to $6.6 million in 2025, then sank by 59.09% to $2.7 million in 2026.
• Business Quant data shows NBIX's Amortization of Deferred Charges at $2.7 million in Q1 2026, $6.6 million in Q3 2025, and $7.1 million in Q2 2025.